All In Biotech

Free tool

FAERS Monitor: Lumizyme

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125291 or its brand name (Lumizyme, Alglucosidase Alfa). Reports on generic versions are filed under their own applications.

Reports

2,436

Serious

921

38% of reports

Hospitalization

540

Death reported

118

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • inappropriate schedule of product administration219
  • pyrexia179
  • off label use153
  • dyspnoea141
  • malaise105
  • fatigue100
  • pneumonia100
  • fall95
  • drug specific antibody present89
  • urticaria87
  • infusion related reaction83
  • rash83
  • pain81
  • weight decreased71
  • asthenia70

Reports by year received

View as table
YearReports
20091
20104
201124
201243
2013153
2014210
2015181
2016143
2017148
2018146
2019182
2020121
2021225
2022263
2023210
2024150
2025130
2026102

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,723 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug specific antibody presentSignal89119.897.510,226
infusion related reactionSignal8310.88.8732
inappropriate schedule of product administrationSignal21910.59.31,888
urticariaSignal874.53.6234
pyrexiaSignal1794.53.9486
pneumoniaSignal1002.72.2104
fallSignal952.52.083
weight decreasedSignal712.21.746
dyspnoeaSignal1412.21.888
malaiseSignal1052.11.758
rash831.61.321
asthenia701.61.316
off label use1531.51.327
pain811.10.91
fatigue1001.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.